Aritinercept for generalized myasthenia gravis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will enroll adults with generalized myasthenia gravis (MGFA class II-IV) to evaluate aritinercept versus placebo. It will assess safety, tolerability, and how the drug is processed by the body, as well as its effects on the illness. The trial includes phase 1 and phase 2 components to explore initial safety signals and potential effectiveness in a controlled setting. Participants will receive either aritinercept or placebo at investigational sites in California and Florida under defined inclusion and exclusion criteria. Primary goals are to determine tolerability and pharmacokinetic/pharmacodynamic profiles, with secondary aims related to clinical efficacy.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Adult patients (18-85 years old)
* Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG
* Additional inclusion criteria are defined in the protocol

Key Exclusion Criteria:

* Current or medical history of malignancy within the last 5 years
* Pregnant, breastfeeding or intending to become pregnant during the Study
* Additional exclusion criteria are defined in the protocol

Where it's running

• Aurinia Investigational Site
  Pasadena, California, United States Recruiting
• Aurinia Investigational Site
  Altamonte Springs, Florida, United States Recruiting
• Aurinia Investigational Site
  Boca Raton, Florida, United States Recruiting
• Aurinia Investigational Site
  Homestead, Florida, United States Recruiting
• Aurinia Investigational Site
  Miami, Florida, United States Recruiting
• Aurinia Investigational Site
  Miami, Florida, United States Recruiting

Study contacts

• Study coordinator: Aurinia Clinical Trials Information
• Email: clinicaltrials@auriniapharma.com
• Phone: 833-606-5975

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MG patient registry to track long-term experiences and treatment patterns

  This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.

  Recruiting Autoimmune Neurology Alliance · Framingham, Massachusetts · NCT07761026

• Panorama: Neuromuscular Organoids to understand refractory AChR+ myasthenia gravis

  This study tests neuromuscular organoids built from stem cells to see if they reveal why some people with AChR-positive myasthenia gravis don’t respond to standard treatments.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07717281

• Claseprubart in adults with generalized myasthenia gravis

  This study tests whether claseprubart can help adults with generalized myasthenia gravis when compared with placebo.

  Recruiting at 11 sites Phase 3 Dianthus Therapeutics · Pasadena, California and 11 other locations · NCT07647510

• MyoSense 360 in generalized myasthenia gravis: testing digital monitoring to track change

  This study tests whether a digital monitoring system can detect meaningful changes in generalized myasthenia gravis over a year in adult patients using a smartphone app and wearable device.

  Recruiting at 2 sites Ad scientiam · Aarhus and 19 other locations · NCT07323316

• Corticosteroid-sparing efgartigimod for elderly AChR-positive generalized myasthenia gravis

  This trial tests whether efgartigimod given IV or under the skin helps people 65 and older with AChR-positive generalized myasthenia gravis reduce their corticosteroid dose while keeping symptoms under control.

  Recruiting at 8 sites Phase 4 Centre Hospitalier Universitaire de Nice · Nice, Alpes-Maritimes and 8 other locations · NCT07072988

• Observational study on ravulizumab for generalized myasthenia gravis

  This study is looking at how well ravulizumab works for people with generalized myasthenia gravis over three years to see how it helps their health.

  Recruiting at 10 sites AstraZeneca · Bydgoszcz and 10 other locations · NCT06909253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.